Siglec-15 is a glyco-immune checkpoint in prostate cancer regulating immune evasion and metastasis
Prostate cancer is a leading cause of cancer-related mortality in men, and effective treatment options are limited for advanced and metastatic disease. The sialoglycan immune checkpoint Siglec-15 has emerged as a key mediator of tumour-associated immune suppression in several malignancies; however, its expression and functional role in prostate cancer remain poorly defined. Here, using dual…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
